Увійти

Готові списки джерел за темами / 159.546.4-053.4/.5 (043.2) / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 159.546.4-053.4/.5 (043.2).

Статті в журналах з теми "159.546.4-053.4/.5 (043.2)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "159.546.4-053.4/.5 (043.2)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Semenova, Lioubov I., Brian W. Skelton, and Allan H. White. "Structural Systematics of Rare Earth Complexes. XVIII (Hydrated) Mononuclear 1 : 1 Adducts of Lanthanoid(III) Chlorides with 2,2′-Bipyridine." Australian Journal of Chemistry 52, no. 6 (1999): 551. http://dx.doi.org/10.1071/ch98049.

Повний текст джерела

Анотація:

Room-temperature single-crystal X-ray structure determinations are recorded for a number of adducts of hydrated lanthanoid(III) chlorides with 2,2′-bipyridine, ‘bpy’, crystallized from water/ethanol solutions, which contain mononuclear arrays with 1 : 1 Ln/bpy stoichiometry. Extended isomorphous series have been defined pertinent to the heavy end of the Ln series: crystals of LnCl3/bpy/H2O (1 : 1 : 6) ([(bpy)Ln(OH2)6]Cl3), seemingly inclusive of (at least) the range Ln = Ho(-)Lu and Y, are monoclinic, P 21/n, a ≈ 14·2, b ≈ 7·7, c ≈ 17·4 Å, β ≈ 91°, Z = 4, with an eight-coordinate LnN2O6 array;

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Bowmaker, Graham A., Effendy, Robert D. Hart, John D. Kildea, and Allan H. White. "Lewis-Base Adducts of Group 11 Metal(I) Compounds. LXXIII Synthesis, Spectroscopy and Structural Systematics of New 1 : 1 'Cubane' Tetramers of Copper(I) and Silver(I) Halides with Triphenylarsine." Australian Journal of Chemistry 50, no. 6 (1997): 653. http://dx.doi.org/10.1071/c96039.

Повний текст джерела

Анотація:

Syntheses and room-temperature single-crystal X-ray structural characterization of a number of 1 : 1 ‘cube tetramer’ adducts of copper(I) and silver(I) halides, MX, with triphenylarsine, AsPh3, are recorded, being [XM(AsPh3)]4. The CuBr adduct, obtained unsolvated from toluene, orthorhombic Pbcn, a 17·844(5), b 20·778(8), c 18·430(4) Å, Z = 4 tetramers, conventional R on |F| 0·058 for No 1309 independent ‘observed’ reflctions (I > 3σ(I)), is isomorphous with previously recorded [ClAg(PPh3)]4, the tetramer having crystallographically imposed 2 symmetry. The CuI adduct, previously recorded as

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Marincowitz, Carl, Omar Bouamra, Tim Coates, et al. "1427 The effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals." Emergency Medicine Journal 39, no. 12 (2022): A960.2—A964. http://dx.doi.org/10.1136/emermed-2022-rcem2.2.

Повний текст джерела

Анотація:

Aims, Objectives and BackgroundThere is evidence that COVID-19 ‘lockdowns’ may have contributed to increased non-accidental injury, domestic violence and self-harm related to deteriorating mental health. Internationally, there is also evidence that the diversion of health care resources may led to worse outcomes for patients presenting with major trauma. There has been no previous national evaluation of ‘lockdown’ measures impact on the characteristics, treatment pathways and outcomes of trauma patients in EnglandWe aimed to assess the impact of successive lockdowns on the volume, demographics

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Zhong, Runbo, Min Yan, Qiming Wang, et al. "Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors." Journal of Clinical Oncology 43, no. 16_suppl (2025): 107. https://doi.org/10.1200/jco.2025.43.16_suppl.107.

Повний текст джерела

Анотація:

107 Background: Nectin-4 is a cell adhesion molecule that is highly expressed in a wide variety of cancers and is associated with poor prognosis. SHR-A2102 is a novel ADC consisting of a fully humanized Nectin-4–directed monoclonal antibody, bound to topoisomerase I inhibitor payload via a cleavable linker. We conducted a multi-center, phase 1 trial to evaluate SHR-A2102 in advanced solid tumors. Methods: Patients (pts) with Nectin-4 positive, locally advanced unresectable or metastatic solid tumors were enrolled. The study included dose-escalation (D-ESC), dose-expansion (D-EXP) and efficacy-

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Akinbobola, Olawale, Meredith Ray, Matthew Paul Smeltzer, et al. "Evolution of overall survival (OS) after curative-intent lung cancer surgery in a population-based Mississippi Delta cohort." JCO Oncology Practice 20, no. 10_suppl (2024): 278. http://dx.doi.org/10.1200/op.2024.20.10_suppl.278.

Повний текст джерела

Анотація:

278 Background: Surgical resection is the most important curative modality for patients with lung cancer, with long-term OS influenced by both surgical quality and cancer biology. We compared surgical care and outcomes over 4 eras in the population-based Mid-South Quality of Surgical Resection (MS-QSR) cohort, an ongoing regional surgical and pathologic quality improvement (QI) dissemination and implementation project. Methods: We implemented a surgical lymph node collection kit and a novel pathology gross dissection method across 12 hospitals encompassing >95% of lung cancer resections in

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Nurbaeva, K., T. Reshetnyak, F. Cheldieva, M. Cherkasova, E. Samarkina, and A. Lila. "AB0116 NEW INFLAMMATORY MARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1188.1–1189. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1331.

Повний текст джерела

Анотація:

BackgroundThromboinflammation is a pathological process that is associated with uncontrolled inflammation, leading to hypercoagulability and thrombotic complications. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are prototypical chronic thromboinflammatory diseases. Neutrophils are important cells in the development of systemic inflammation and thrombosis. Neutrophil reactivity (NEUT-RI), neutrophil granularity (NEUT-GI), immature granulocytes (IG), and neutrophil-to-lymphocyte ratio (NLR) are considered as inflammatory markers.ObjectivesTo determine the role of param

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Poptsov, V. N., V. M. Zakharevich, E. A. Spirina, et al. "HEART TRANSPLANTATION FROM DONORS WITH LEFT VENTRICULAR EJECTION FRACTION <40%." Russian Journal of Transplantology and Artificial Organs 20, no. 2 (2018): 29–36. http://dx.doi.org/10.15825/1995-1191-2018-2-29-36.

Повний текст джерела

Анотація:

Aim.Purpose of study was evaluated of early outcomes of HT performed from donors with LVEF <40%.Materials and methods.The study included 18 (14 men and 4 women, age 29 to 59 (42.9 ± 2.7) years) recipients who received cardiac allograft from donors with LVEF <40%. The urgency of HT was 1A-B (n = 16) and 2 status (n = 2) UNOS. 11 (55,6%) patients needed peripheral VA ECMO.Results.Heart donors (13 men and 5 women, 22 to 57 (39.1 ± 3) years) were the traumatic (n = 3) and non-traumatic (n = 15) brain damage. Maximal inotropic support was norepinephrine 433 ± 46.2 ng/kg /min (n = 14) and dopa

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Kwon, H., S. Lee, S. Oh, S. Kim, and H. Kim. "Phase II study of mFOLFOX-4 followed by mFOLFIRI in advanced gastric cancer." Journal of Clinical Oncology 27, no. 15_suppl (2009): e15546-e15546. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15546.

Повний текст джерела

Анотація:

e15546 Background: FOLFOX followed by FOLFIRI regimen has been commonly used in colorectal cancer. This combination has also been evaluated in a number of phase II studies in the first- and second-line treatment setting of advanced gastric cancer. We have evaluated the efficacy and toxicity of modified FOLFOX-4 followed by modified FOLFIRI regimens in advanced gastric cancer patients. Methods: Previously untreated patients with advanced or recurrent gastric cancer were enrolled. As first-line therapy, patients received modified FOLFOX-4, bolus ldLV 50mg followed by a 5-FU bolus 400mg/m2 and 22

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Tolpygina, S. N., A. V. Zagrebelny, M. I. Chernysheva, et al. "Long-term survival of patients with cerebrovascular accident, depending on sex and age: data from the REGION-M registry." Cardiovascular Therapy and Prevention 22, no. 7 (2023): 3596. http://dx.doi.org/10.15829/1728-8800-2023-3596.

Повний текст джерела

Анотація:

Aim. To study the long-term survival of patients with cerebrovascular accident, depending on sex and age.Material and methods. The outpatient part of the REGION-M registry (patients with cerebrovascular accident, hospitalized in a Moscow hospital) included 684 patients assigned to the City Polyclinic № 64 (Moscow), discharged from the F. I. Inozemtsev City Clinical Hospital (Moscow) in the period from January 1, 2012 to April 30, 2017 with a diagnosis of stroke, which were divided into 5 age groups: group 1 — ≤50 years, n=72 (10,5%), group 2 — 51-60 years old, n=122 (17,8%), group 3 — 61-70 ye

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Fleischmann, R., M. C. Genovese, K. Maslova, H. Leher, A. Praestgaard, and G. R. Burmester. "FRI0092 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 624–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1946.

Повний текст джерела

Анотація:

Background:Sarilumab is a human IL-6 receptor (IL-6R) inhibitor approved for the treatment of adults with moderate to severely active rheumatoid arthritis (RA). In the TARGET study (NCT01709578), sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) significantly improved signs and symptoms of RA and physical function versus placebo in patients refractory to tumor necrosis factor (TNF) inhibitors.Objectives:Here we report the long-term safety and efficacy of subcutaneous (SC) sarilumab over 5 years in patients who continued treatment in the open-label extension s

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Lehrer, Brittany J., Glodi Mutamba, Katie A. Thure, et al. "Optimal Pediatric Outpatient Antibiotic Prescribing." JAMA Network Open 7, no. 10 (2024): e2437409. http://dx.doi.org/10.1001/jamanetworkopen.2024.37409.

Повний текст джерела

Анотація:

ImportanceIn the US, 50% of all pediatric outpatient antibiotics prescribed are unnecessary or inappropriate. Less is known about the appropriateness of pediatric outpatient antibiotic prescribing.ObjectiveTo identify the overall percentage of outpatient antibiotic prescriptions that are optimal according to guideline recommendations for first-line antibiotic choice and duration.Design, Setting, and ParticipantsThis cross-sectional study obtained data on any clinical encounter for a patient younger than 20 years with at least 1 outpatient oral antibiotic, intramuscular ceftriaxone, or penicill

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Giné, Eva, Sílvia Beà, Alba Navarro, et al. "Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases." Blood 124, no. 21 (2014): 1677. http://dx.doi.org/10.1182/blood.v124.21.1677.1677.

Повний текст джерела

Анотація:

Abstract Introduction: MCL is a mature B-cell neoplasm characterized by t(11;14) (q13;q32) and cyclin D1 (CCND1) overexpression. Molecular studies have revealed other alterations in cell-cycle regulation, DNA damage response and cell survival pathways, with a landscape of somatic mutations being recently identified. CNS involvement is a well known complication, occurring in 4-26% of MCL at five years, with an ominous significance. Although different clinical variables have been identified as risk factors for CNS infiltration, the biological parameters related to this complication have not been

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Martínez-Pastor, F., M. R. Fernández-Santos, E. del Olmo, et al. "159 WASHING INCREASES THE VULNERABILITY OF RED DEER THAWED SPERMATOZOA TO OXIDATIVE STRESS." Reproduction, Fertility and Development 21, no. 1 (2009): 178. http://dx.doi.org/10.1071/rdv21n1ab159.

Повний текст джерела

Анотація:

This study is an attempt to increase our knowledge on the effect that sperm preparation techniques have on thawed spermatozoa from wild ruminants. Semen banks for wild species can be maintained and used for artificial insemination and IVF, but it is necessary to optimize spermwork. Our objective was to assess the effect of centrifugation, dilution and oxidative stress on viability of cryopreserved sperm in the Iberian red deer (Cervus elaphus hispanicus), considering the hypothesis that washing increases the susceptibility of red deer thawed spermatozoa to oxidative stress. We used epididymal

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Blum, William, Ben Sanford, Rebecca B. Klisovic, et al. "Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)." Blood 120, no. 21 (2012): 44. http://dx.doi.org/10.1182/blood.v120.21.44.44.

Повний текст джерела

Анотація:

Abstract Abstract 44 CALGB (now part of the Alliance for Clinical Trials in Oncology) performed a non-randomized phase II study testing one year (yr) of investigational maintenance therapy with decitabine for newly diagnosed adult AML patients (pts) <60 yrs of age (CALGB 10503, Alliance). The study included induction followed by molecular and cytogenetic risk-adapted consolidation identical to that given in the prior CALGB study for younger AML pts (19808). Induction used daunorubicin 90 mg/m2 for 3 days, etoposide 100 mg/m2 for 3 days, and cytarabine 100 mg/m2 for 7 days (3+3+7). Reinducti

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Nakayama, Y., R. Nakashima, T. Handa, et al. "POS1051 LUNG CLUSTERING ANALYSIS-BASED PHENOTYPES OF RHEUMATOID ARTHRITIS USING ARTIFICIAL INTELLIGENCE-BASED TECHNOLOGY FOR CHEST COMPUTED TOMOGRAPHY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 843.1–844. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2178.

Повний текст джерела

Анотація:

BackgroundLung involvement is a prevalent extraarticular manifestation of rheumatoid arthritis (RA) that remains a significant clinical challenge. Few studies have comprehensively quantified lung abnormalities of RA patients using artificial intelligence-based (AI) technology.ObjectivesThe aim of this study was to quantify lung lesions in RA patients and classify them based on their lung parameters.MethodsAn AI-based quantitative computed tomography (CT) image analysis software (AIQCT) was applied to high-resolution CT scans of RA patients in a cross-sectional manner. AIQCT automatically class

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Choueiri, Toni K., Pooja Ghatalia, Guillermo de Velasco, et al. "39 Safety profile of belzutifan monotherapy in patients with renal cell carcinoma: A pooled analysis of 4 clinical trials." Oncologist 29, Supplement_1 (2024): S2—S3. http://dx.doi.org/10.1093/oncolo/oyae181.004.

Повний текст джерела

Анотація:

Abstract Background The first-in-class hypoxia-inducible factor-2α inhibitor, belzutifan, is indicated in the United States for the treatment of certain patients with von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors not requiring immediate surgery and for patients with advanced RCC previously treated with a PD-(L)1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor. Due to its unique mechanism of action, belzutifan has a distinct safety profile. We characterized the saf

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Sierra-Díaz, Diana Carolina, Adrien Morel, Dora Janeth Fonseca, et al. "Abstract P3-07-05: Genetic profile of germline mutations in unselected women with breast cancer in a Colombian population." Cancer Research 82, no. 4_Supplement (2022): P3–07–05—P3–07–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-07-05.

Повний текст джерела

Анотація:

Abstract Introduction In Colombia Breast cancer (BC), is the most frequent and has the highest mortality rate among all types of cancer. There are few studies of the genomic profile in unselected affected population by BC in Colombia. Some of these studies have only tested the presence of variants reported as founders named “Colombian Profile”.We conducted a large-scale genomic analysis using Whole Exome Sequencing (WES) to evaluate germline mutations in unselected BC patients. Methods This trial included 299 unselected BC female patients aged over 18 years old, without personal and family his

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Alinovskaya, Ludmila I., Sergey E. Sedykh, Nikita V. Ivanisenko, Svetlana E. Soboleva, and Georgy A. Nevinsky. "How human serum albumin recognizes DNA and RNA." Biological Chemistry 399, no. 4 (2018): 347–60. http://dx.doi.org/10.1515/hsz-2017-0243.

Повний текст джерела

Анотація:

AbstractWe show here for the first time that HSA possesses two nucleic acid-(NA) binding sites and we estimated the relative contributions of the nucleotide links of (pN)nto their total affinity for these binding sites with higher and lower affinity for NAs. The minimal ligands of these binding sites areorthophosphate (Kd=3.0 and 20.0 mm), various dNMPs (5.6–400 μmand 0.063–18 mm) and different rNMPs (4.9–30 μmand 14–250 μm). Maximal contribution to the total affinity of all NAs to the first and second sites was observed for one nucleotide and was remarkably lower for three additional nucleoti

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Castrejon, I., J. Molina Collada, C. Perez-Garcia, et al. "POS1439 CANCER IN PATIENTS WITH RHEUMATIC DISEASES EXPOSED TO DIFFERENT BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN REAL-WORLD CLINICAL PRACTICE: DATA FROM A MULTICENTER REGISTER." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1063. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3834.

Повний текст джерела

Анотація:

BackgroundExtensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk of cancer in biologic (bDMARDs) different to anti-TNF and targeted synthetic (tsDMARDs) is considerably less investigated. As new therapies are emerging, more data in real-world registries are needed to confirm safety in other treatment groups.ObjectivesTo compare the risk of cancer of tsDMARDs and other bDMARDs versus anti-TNF in patients with rheumatic diseases.MethodsData of patients enrolled in BIOBADASER 3.0 up

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Sasaki, Koji, Nina Shah, Qaiser Bashir, et al. "Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant." Blood 126, no. 23 (2015): 3194. http://dx.doi.org/10.1182/blood.v126.23.3194.3194.

Повний текст джерела

Анотація:

Abstract Introduction: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HCT) is the standard of care for younger patients with newly diagnosed multiple myeloma (MM). In approximately 15% of MM patients the monoclonal (M) spike consists of k or l light chains only as opposed to heavy + light chains. It remains unclear whether light chain (LC) MM has a different prognosis compared to other monoclonal protein subtypes after an auto-HCT. Methods: We retrospectively analyzed 1067 patients with MM who underwent auto-HCT between January 1, 2004 and January 1

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Kádár, Imre, and Péter Ragályi. "Study of mineral fertilizer effects on an 8-year-old planted sward." Agrokémia és Talajtan 62, no. 1 (2013): 115–32. http://dx.doi.org/10.1556/agrokem.62.2013.1.8.

Повний текст джерела

Анотація:

Egy műtrágyázási kísérlet (35. évében, 2008-ban) vizsgáltuk az eltérő N-, P- és K-ellátottsági szintek és kombinációik hatását a réti csenkesz (Festuca pratensis) vezérnövényű nyolckomponensű pillangós nélküli gyepkeverék 8. évének termésére és ásványi elemtartalmára. A termőhely talaja a szántott rétegben mintegy 3% humuszt, 3–5% CaCO3-ot és 20–22% agyagot tartalmazott, N és K elemekben közepesen, P és Zn elemekben gyengén ellátottnak minősült. A kísérlet 4N×4P×4K = 64 kezelést×2 ismétlést = 128 parcellát foglalt magában. A talajvíz 13–15 m mélyen helyezkedik el, a terület aszályérzékeny. A k

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Magnus, Dan, Santosh Bhatta, and Julie Mytton. "432 Establishing injury surveillance in emergency departments in Nepal: epidemiology and burden of paediatric injuries." Emergency Medicine Journal 37, no. 12 (2020): 825.2–827. http://dx.doi.org/10.1136/emj-2020-rcemabstracts.7.

Повний текст джерела

Анотація:

Aims/Objectives/BackgroundGlobally, injuries cause more than 5 million deaths annually. Children and young people are a particularly vulnerable group and injuries are the leading cause of death in people aged 5–24 years globally and a leading cause of disability.In most low and middle-income countries where the majority of global child injury burden occurs, systems for routinely collecting injury data are limited. There is a continuing need for better data on childhood injuries and for injury surveillance.The aim of our study was to introduce a hospital-based injury surveillance tool – the fir

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Sorokina, L., I. Avrusin, R. Raupov, et al. "POS1299 RISK FACTORS OF TOTAL HIP ARTHROPLASTY IN JUVENILE ARTHRITIS WITH HIP INVOLVEMENT." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 931–32. http://dx.doi.org/10.1136/annrheumdis-2021-eular.857.

Повний текст джерела

Анотація:

Background:Hip osteoarthritis (HOA) is a severe outcome of juvenile idiopathic arthritis (JIA) itself and also can be result of corticosteroid (CS) treatment, if it was used. Total hip arthroplasty (THA) is the last step in JIA treatment and indicates ineffectiveness of conservative treatment.Objectives:We aimed to evaluate risk factors which lead to THA in JIA patients with HOA.Methods:753 patients aged 2-17 years were included in our retrospective study during the last 10 years. Diagnosis was made according to ILAR criteria. Clinical, laboratory and radial examinations were evaluated. Diagno

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Liao, Wei, Matthew Paul Smeltzer, Jordan Goss, et al. "Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta." Journal of Clinical Oncology 43, no. 16_suppl (2025): 8002. https://doi.org/10.1200/jco.2025.43.16_suppl.8002.

Повний текст джерела

Анотація:

8002 Background: The LCDR in the CT screened cohort in the National Lung Screening Trial (NLST) was 1.1% over a median of 6.5 years follow up. We evaluated the LCDR in a regional US community. Methods: Prospective cohort study of patients in LCS and IPN programs in 22 facilities across a 125 county service area population. We compared LCDR over 3 years in LCS stratified by Lung-RADS (L-R) score (1 to 4X), IPN by nodule size (≤6, >6-15, >15-20, >20-30 mm) on initial CT scans. Comparisons used Chi-square tests, Wilcoxon tests, and Cox regression models with Hazard Ratios (HR) for lung c

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Abu-Khalaf, Maysa, Fnu Nikita, Ayako Shimada, et al. "Abstract P4-11-32: Change in body mass index in breast cancer survivors." Cancer Research 82, no. 4_Supplement (2022): P4–11–32—P4–11–32. http://dx.doi.org/10.1158/1538-7445.sabcs21-p4-11-32.

Повний текст джерела

Анотація:

Abstract Background: Obesity is associated with an increased risk of breast cancer recurrence and poor survival. Obesity rate in adults in the city of Philadelphia is high, with non-Hispanic blacks and Hispanics having the highest rates. We sought to evaluate changes in body mass index (BMI) in breast cancer survivors within the first 2 years from initial encounter for a breast cancer (BC) diagnosis (dx), and investigate factors that may correlate with a change in BMI. Methods: We identified 5,423 BC patients (pts) in our electronic medical record, (1/2015-present), using ICD-10 code C50.X. We

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Loyaux, Romain, Julien Hadoux, Sandrine Oziel, et al. "Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors." Blood 144, Supplement 1 (2024): 1289. https://doi.org/10.1182/blood-2024-204958.

Повний текст джерела

Анотація:

Background . In advanced/metastatic neuroendocrine tumors (NETs), PRRT (Peptide Receptor Radionuclide Therapy), has shown efficacy but with significant hematologic toxicity, including therapy-related myeloid neoplasms (t-MN). Here, we assessed the effect of PRRT on the development of clonal hematopoiesis (CHIP) or clonal cytopenia of undetermined significance (CCUS) known to be a risk factor for t-MN development. Methods . We performed a targeted 77 genes mutational analysis using Next Generation Sequencing (NGS) in blood samples of 153 patients with metastatic gastroenteropancreatic (GEP) NET

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Shen, Lin, Thierry Andre, Hyun Cheol Cheol Chung, et al. "Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer." Journal of Clinical Oncology 42, no. 3_suppl (2024): 109. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.109.

Повний текст джерела

Анотація:

109 Background: NTRK gene fusions are oncogenic drivers in various tumors. Laro, a highly selective, central nervous system-active TRK inhibitor, is approved for tumor-agnostic use in pts with TRK fusion cancer, based on a rapid, robust, and durable objective response rate (ORR) in various cancers. We report data on a subset of pts with TRK fusion GI cancer treated with laro with longer follow-up. Methods: Pts with TRK fusion GI cancer in the phase II clinical trial NAVIGATE (NCT02576431) were included. Responses were independent review committee (IRC)-assessed (RECIST v1.1). Results: As of Ju

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Duarte, Rafael F., Julio Delgado-Gonzalez, Bronwen E. Shaw, et al. "Pathologic Features May Predict the Clinical Outcome of Hepatic Graft Versus Host Disease (H-GVHD)." Blood 104, no. 11 (2004): 5079. http://dx.doi.org/10.1182/blood.v104.11.5079.5079.

Повний текст джерела

Анотація:

Abstract Liver histology is regarded as inadequate for grading the severity of H-GVHD. Thus, liver biopsies (LB) are only performed to rule out other causes of liver injury when the results may lead to a radical therapeutic change. In this study we reviewed the pathologic features in LB from 33 consecutive evaluable patients with at least one LB, confirmed diagnosis of H-GVHD and no other concomitant causes of liver dysfunction. We asked whether the pathologic features in the first LB may predict their clinical outcome. Underlying diseases were AML (9), ALL (8), CML (7), MM (4), MDS (3), NHL (

Стилі APA, Harvard, Vancouver, ISO та ін.

29

McGill, J., G. Reddy, L. Simon, and G. Wirtu. "175 EFFECT OF ACETYL-CoA CARBOXYLASE (ACC) INHIBITOR ON THE LIPID CONTENT AND NUCLEAR MATURATION OF CANINE OOCYTES." Reproduction, Fertility and Development 26, no. 1 (2014): 202. http://dx.doi.org/10.1071/rdv26n1ab175.

Повний текст джерела

Анотація:

Compared with other domestic species, embryo technologies are least developed for the dog. This is mainly due to difficulties in producing mature oocytes in vitro. Canine oocytes contain exceptionally high amounts of lipid. High lipid content increases the chilling sensitivity of oocytes and embryos. Mechanical and chemical reductions of the lipid content have been used to improve the cryotolerance of oocytes. Additionally, chemical stimulation of lipid catabolism improved oocyte in vitro maturation (IVM) rates in other species (You et al. 2012 Theriogenology 78, 235–543). Acetyl-CoA carboxyla

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Theodorakakou, Foteini, Despina Fotiou, Vasiliki Spiliopoulou, et al. "Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis." Blood 144, Supplement 1 (2024): 4674. https://doi.org/10.1182/blood-2024-203780.

Повний текст джерела

Анотація:

Introduction: Almost 50% of patients (pts) with light chain (AL) amyloidosis, harbor translocation t(11;14) on their clonal plasma cells and as a result, these cells overexpress BCL-2. Venetoclax is a selective BCL-2 inhibitor that has been shown to induce high rates of deep hematologic responses in patients with plasma cell malignancies harboring t(11;14), including pts with AL. However, the efficacy of venetoclax has not been evaluated in AL in the context of prospective studies, and retrospective case-series remain the only source of data. Here we present our experience in patients with AL

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Holubar, Stefan, Samuel Eisenstein, Liliana Bordeianou, et al. "CURRENT VENOUS THROMBOEMBOLISM CHEMOPROPHYLAXIS PRACTICES AFTER SURGERY FOR IBD: SAVES-IBD TRIAL INITIAL REPORT." Inflammatory Bowel Diseases 28, Supplement_1 (2022): S40. http://dx.doi.org/10.1093/ibd/izac015.060.

Повний текст джерела

Анотація:

Abstract BACKGROUND Despite standard of care chemoprophylaxis, postoperative VTEs occur in ∼4% of IBD patients, and little data on current practices in IBD has been reported. We cultivated a baseline cohort to inform power calculations for a forthcoming prospective, multicenter trial of VTE prophylaxis comparing the efficacy & safety of standard of care vs. aspirin (SAVES-IBD Trial). In this initial report we describe the current standard of care VTE prophylaxis practice patterns in our collaborative. METHODS The National Surgical Quality Improvement Program (NSQIP) IBD Collaborative desig

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Yang, Y. G., and X. H. Wu. "First Report of Potato Stem Canker Caused by Binucleate Rhizoctonia AG-A in Jilin Province, China." Plant Disease 97, no. 9 (2013): 1246. http://dx.doi.org/10.1094/pdis-10-12-0912-pdn.

Повний текст джерела

Анотація:

Potato (Solanum tuberosum L.) stem canker caused by Rhizoctonia solani occurs in potato-growing regions all over the world and can result in severe losses in crop yield and quality. In late July 2011, potato subterraneous stems with stem cankers composed of brownish, sunken lesions were observed at 15% incidence in seven sites in Jilin Province, northeast China. Samples were collected, and stem pieces (each 5 mm long) taken from the margins of the healthy and diseased tissues were surface-disinfested with 0.5% NaOCl for 2 min, rinsed with sterilized water, dried, then placed on potato dextrose

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Graham, H. K., and A. W. Trafford. "Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure." American Journal of Physiology-Heart and Circulatory Physiology 292, no. 3 (2007): H1364—H1372. http://dx.doi.org/10.1152/ajpheart.00355.2006.

Повний текст джерела

Анотація:

The cardiac extracellular matrix (ECM) maintains the structural and mechanical integrity of the myocardium. We determined the alterations in the composition of the ECM coincident with the transition from compensated left ventricular (LV) hypertrophy (LVH) to symptomatic congestive heart failure (CHF) and the mechanisms underlying such changes. Heart failure was induced in ferrets by aortic banding. Myocardial collagen content was assessed by HPLC and histological analysis. Matrix metalloproteinase (MMP) activity and tissue inhibitor of metalloproteinase (TIMP) expression were evaluated using g

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Van der Heijde, D., X. Baraliakos, M. Dougados, et al. "OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 12–13. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2441.

Повний текст джерела

Анотація:

BackgroundBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In a phase 2b study, BKZ showed rapid and sustained efficacy and was well tolerated up to 156 weeks (wks) in patients (pts) with active ankylosing spondylitis (AS).1,2ObjectivesTo assess efficacy and safety of BKZ vs placebo (PBO) in pts with active AS up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 2.MethodsBE MOBILE 2 (NCT03928743) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were aged ≥18 yrs, met modified New York criteria

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Cappellini, Maria Domenica, Amal El-Beshlawy, Antonis Kattamis, et al. "Efficacy and Safety of Deferasirox (Exjade®) in Patients with Transfusion- Dependent Anemias: 1-Year Results from the Large, Prospective, Multicenter EPIC Study." Blood 112, no. 11 (2008): 3875. http://dx.doi.org/10.1182/blood.v112.11.3875.3875.

Повний текст джерела

Анотація:

Abstract Background: Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy for treating transfusional iron overload. In registration trials, the starting dose was based on baseline liver iron concentration (LIC). The prospective multicenter EPIC trial, the largest ever conducted for an iron chelator, included patients (pts) with a variety of transfusion-dependent anemias and was designed to evaluate the efficacy and safety of fixed starting doses of deferasirox based on transfusion history, with subsequent dose titration based on serum ferritin (SF) trends. On

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Dörner, T., Y. Tanaka, M. Mosca, et al. "POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 639.1–639. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2375.

Повний текст джерела

Анотація:

BackgroundBaricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, has been evaluated in clinical studies in patients with systemic lupus erythematosus (SLE).ObjectivesTo assess the safety profile of BARI in patients with SLE.MethodsPatients with SLE receiving stable background therapy were randomised 1:1:1 to BARI 2-mg, 4-mg, or placebo (PBO) once daily in one 24-week, phase 2 (NCT02708095) and two 52-week, phase 3, PBO controlled studies (NCT03616912 and NCT03616964).ResultsA total of 1,849 patients were

Стилі APA, Harvard, Vancouver, ISO та ін.

37

De Montalembert, Mariane, Frédéric Galacteros, Jean Antoine Ribeil, et al. "Implementation of a European Cohort to Follow Sickle Cell Children and Adults Treated with Hydroxycarbamide." Blood 124, no. 21 (2014): 564. http://dx.doi.org/10.1182/blood.v124.21.564.564.

Повний текст джерела

Анотація:

Abstract Hydroxycarbamide (HU) is a myelosuppressive drug marketed since 1968 for the treatment of hematological cancer, and authorized since 2007 in Europe as orphan medicinal product for the prevention of recurrent vaso-occlusive crises including acute chest syndrome in adults and children older than 2 years with sickle cell disease (SCD). ESCORT-HU (European Sickle Cell Disease Cohort – Hydroxyurea) is a multicenter prospective non interventional study implemented in Europe to collect more information about the safety profile of HU and morbi-mortality in SCD patients treated with HU. The st

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Biswas, Sourav, Zeba Khanam, Asraful Alam, and Lakshminarayan Satpati. "Progress and determinants of household access to improved drinking water in India using a Water Access Index: insights from the National Family Health Survey towards achieving SDG 6.1." BMJ Open 15, no. 6 (2025): e091269. https://doi.org/10.1136/bmjopen-2024-091269.

Повний текст джерела

Анотація:

Background and objectiveAccess to clean drinking water is essential for health and development. Despite global and national initiatives, many regions in India continue to face inadequate water access. This study assesses progress, sociodemographic determinants and geographic disparities in access to drinking water in India, aligning with Sustainable Development Goal (SDG) 6.1.DesignThis study used secondary data from five rounds of the National Family Health Survey (NFHS-1 to NFHS-5; 1992–2021), nationally representative surveys conducted across India. Logistic regression was employed to exami

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Creutzig, Ursula, Zimmermann Martin, Michael Dworzak, et al. "Excellent Outcome In Infants below One Year of Age with AML – Results of Studies AML-BFM -98 and -2004." Blood 116, no. 21 (2010): 17. http://dx.doi.org/10.1182/blood.v116.21.17.17.

Повний текст джерела

Анотація:

Abstract Abstract 17 Infants <1 year of age with AML are very vulnerable patients who may not tolerate intensive treatment, which is however required to achieve complete remission (CR) and long-term survival. In several pediatric AML studies, outcome of this age group is described as unfavorable. Here we report the improved outcome of 108 infants with AML (Down syndromes excluded) who were treated within the studies AML-BFM 98 and -2004 until end of 2008. Treatment regimens of study AML-BFM 98 (see Creutzig, J Clin Oncol 24, 2006) and AML-BFM 2004 were largely similar. AML-BFM 2004: Inducti

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Garcia-Manero, Guillermo, Daniel R. Couriel, Francesco Paolo Tambaro, et al. "A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS)." Blood 114, no. 22 (2009): 119. http://dx.doi.org/10.1182/blood.v114.22.119.119.

Повний текст джерела

Анотація:

Abstract Abstract 119 The role of hypomethylating agents is well established in patients with higher risk MDS. The activity and safety of these agents in patients with lower risk (IPSS low or int-1) is not well understood. We hypothesized based on prior in vitro data and cumulative experience with different routes of administration that subcutaneous (SQ) administration of decitabine (5-aza-2'-deoxycitidine) administered either daily for 3 days or weekly times 3 both every 4 weeks will be safe and active in patients with lower risk MDS. To test this hypothesis, we designed a phase II “play the

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Betz, Martin, James Stempien, Sachin Trevidi, and Rhonda Bryce. "A determination of emergency department pre-triage times in patients not arriving by ambulance compared to widely used guideline recommendations." CJEM 19, no. 04 (2016): 265–70. http://dx.doi.org/10.1017/cem.2016.398.

Повний текст джерела

Анотація:

ABSTRACT Objectives Emergency department (ED) lengths of stay are measured from the time of patient registration or triage. The time that patients wait in line prior to registration and triage has not been well described. We sought to characterize pre-triage wait times and compare them to recommended physician response times, as per the Canadian Triage and Acuity Scale (CTAS). Methods This observational study documented the time that consenting patients entered the ED and the time that they were formally registered and triaged. Participants’ CTAS scores were collected from the electronic recor

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Li, Weimin, Athena Matakidou, Zara Ghazoui, et al. "Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies." Journal of Clinical Oncology 38, no. 15_suppl (2020): 6548. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6548.

Повний текст джерела

Анотація:

6548 Background: Baseline tumor and germline biomarkers in R/M HNSCC were analyzed for predictive potential in pts benefitting from D or D+T. Methods: In HAWK (NCT02207530), 112 pts (PD-L1 tumor cells [TC]≥25%) received D (10 mg/kg Q2W for ≤12 m); in CONDOR (NCT02319044), 67 pts (PD-L1 TC < 25%) received D (10 mg/kg Q2W for ≤12 m), 133 pts received D+T (D 20 mg/kg Q4W, T 1 mg/kg Q4W for ≤12 m), and 67 pts received T (10 mg/kg Q4W [7 doses] then Q12W [2 doses] for ≤12 m) VENTANA PD-L1 (SP263) Assay determined PD-L1 status. Paired FFPE archival tumor and PBMC samples (as germline control) in

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Bauman, Glenn, Mohammed Rashid, Deanna L. Langer, et al. "A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men." Journal of Clinical Oncology 43, no. 5_suppl (2025): 35. https://doi.org/10.1200/jco.2025.43.5_suppl.35.

Повний текст джерела

Анотація:

35 Background: PREP was initiated in Ontario to provide access and characterize performance of PSMA PET CT among men with recurrent prostate cancer after primary definitive treatment (RP or RT). Methods: Between 03/18 and 09/22, 4135 men were accrued. Men were enrolled and imaged with 18F-DCFPyL at 1 of 6 participating sites within 1 of 6 clinical cohorts. Standardized reports delineated sites of recurrence and post PET management changes. Linkage to provincial databases allowed estimation of overall survival and utilization of salvage radiotherapy after PET. Results: Median follow-up was 1.8

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Singhal, Seema, David S. Siegel, Thomas Martin, et al. "Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis." Blood 118, no. 21 (2011): 1876. http://dx.doi.org/10.1182/blood.v118.21.1876.1876.

Повний текст джерела

Анотація:

Abstract Abstract 1876 Carfilzomib (CFZ), a next-generation proteasome inhibitor that selectively and irreversibly binds to its target, resulting in sustained inhibition absent of off-target effects relative to bortezomib, is being evaluated in MM patients. The selectivity of CFZ for the proteasome may explain the low rates of peripheral neuropathy (PN) relative to historical data for bortezomib (BTZ). Safety data have been compiled for >700 patients who received CFZ in 9 Phase (Ph) 1 or 2 trials, 4 of which are completed. The majority of patients had relapsed and refractory (R/R) MM, and m

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Regierer, A., A. Weiß, M. Bohl-Buehler, et al. "OP0225 DEPRESSIVE SYMPTOMS IN PSA: A CROSS-SECTIONAL ANALYSIS FROM THE NATIONAL GERMAN RABBIT-SPA REGISTRY." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 135.2–136. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2130.

Повний текст джерела

Анотація:

Background:Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the musculoskeletal system as well as skin and nails. The prevalence of depression in psoriasis and PsA is high and ranges from 7-40% [1]. Persistent depressive mood may influence disease activity outcome in PsA, especially patient-reported outcomes.Objectives:To assess the correlation of depressive symptoms with PsA-specific outcome parameters.Methods:RABBIT-SpA is a prospective longitudinal cohort study including PsA patients enrolled at start of a new conventional treatment or b/tsDMARD treatment. In regularly

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Повний текст джерела

Анотація:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Kornblit, Brian, Billanna Hwang, Barry Storer, et al. "Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers." Blood 118, no. 21 (2011): 1891. http://dx.doi.org/10.1182/blood.v118.21.1891.1891.

Повний текст джерела

Анотація:

Abstract Abstract 1891 Plerixafor is a novel stem cell mobilizing agent that functions by blocking the interaction between the CXCR4 receptor and stromal-derived factor 1a. Several studies have suggested that compared to granulocyte colony stimulating factor (G-CSF), plerixafor mobilizes peripheral blood stem cells (PBSC) with a greater capacity for bone marrow homing and repopulation. Prior studies have shown that plerixafor-mobilized PBSC (P-PBSC) can induce long term donor engraftment in major histocompatibility complex matched hematopoietic cell transplantation (HCT). In the current study

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Rodeghiero, Francesco, Andrew Provan, Michael Steurer, Bertrand Godeau, Nancy Carpenter, and Georg Kreuzbauer. "Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)." Blood 124, no. 21 (2014): 4199. http://dx.doi.org/10.1182/blood.v124.21.4199.4199.

Повний текст джерела

Анотація:

Abstract Introduction: Romiplostim is a thrombopoietin receptor agonist approved for use in adult pts with ITP. Pooled analyses of combined pt data from romiplostim ITP clinical studies have previously been reported. Here we report updated safety and efficacy data according to baseline splenectomy status. Methods: Data from adult pts in 13 completed ITP studies with romiplostim were analysed up to June 2014. Pts received romiplostim, placebo or medical standard of care (SOC) and data from the placebo/SOC arms were pooled. All 13 studies were included in analyses of baseline pt characteristics

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Moyers, Justin Tyler, Danielle Brazel, Priyanka Kumar, et al. "Abstract 2184: Landscape of genomic alterations of ultra-rare sarcomas (URS) from 1,079 patients in the AACR GENIE real world database: Clinical implications." Cancer Research 82, no. 12_Supplement (2022): 2184. http://dx.doi.org/10.1158/1538-7445.am2022-2184.

Повний текст джерела

Анотація:

Abstract Introduction: Sarcomas are heterogenous tumors of more than 150 different tumor types. Recently, 56 soft tissue (ST-URS) and 21 bone (B-URS) sarcomas were classified as URS based on incidence of less than 1 in a million by the Connective Tissue Oncology Society. There is only one histology-based treatment approved in URS. Methods: AACR GENIE database cBioPortal were accessed. Individual alterations annotated by OncoKB therapeutic evidence level, TCGA PanCancer pathway alterations, and demographic data were gathered. Detailed cancer type was reclassified into genomically distinct disea

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Monteith, Bethany E., Esther Masih-Khan, Eshetu G. Atenafu, et al. "Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience." Blood 126, no. 23 (2015): 5361. http://dx.doi.org/10.1182/blood.v126.23.5361.5361.

Повний текст джерела

Анотація:

Abstract Background The incorporation of novel agents (NA) for multiple myeloma (MM) has improved the response rates (RR), overall survival (OS), and progression free survival (PFS) when compared to conventional agents (CA). Unfortunately, relapse is inevitable and few studies focus on patterns of relapse, especially in non-transplant patients (pts). We aim to describe the different patterns of relapse in non-transplant MM pts and determine if any pre-treatment clinical or disease characteristics can predict the patterns relapse. We will evaluate whether NA treated pts have higher rates of agg

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!